穿皮冠状动脉干预后冠状动脉微循环功能障碍:发病,诊断和治疗策略
Jin BoYuan1, Wang TingTing2, Hua ChengJun1
1National Regional (Traditional Chinese Medicine) Cardiovascular Diagnosis and Treatment Center, Heart Center of the First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China.
Frontiers in cardiovascular medicine
|December 1, 2025
概括
穿皮冠状动脉干预 (PCI) 后的冠状动脉微血管功能障碍 (CMD) 会导致心痛. 了解CMD的发病,诊断和治疗对于改善PCI结果和患者护理至关重要.
科学领域:
- 心脏病学 心脏病学
- 血管生物学 血管生物学
- 干预心脏病学 干预心脏病学
背景情况:
- 冠状动脉微血管功能障碍 (CMD) 是皮肤穿冠状动脉干预 (PCI) 后的慢性心痛复发的重要原因.
- 后PCICMD的根本原因是复杂的,通常不完全理解,限制治疗的有效性.
- 冠状动脉疾病可能导致严重的心血管不良事件.
研究的目的:
- 审查冠状动脉微循环的生理作用.
- 总结了解PCI后CMD的发病,诊断和治疗方面的最新进展.
- 确定关键的研究差距和未来的CMD管理方向.
主要方法:
- 冠状动脉微循环生理学的文献综述.
- 对PCI后CMD病因学和临床表现的当前研究的综合.
- 对CMD的诊断和治疗策略的分析.
主要成果:
- 在PCI之后,CMD是心痛的主要驱动因素.
- 后PCICMD的复杂病因提出了诊断和治疗方面的挑战.
- 目前对CMD病变发生,诊断和治疗的理解需要进一步的研究.
结论:
- 进一步的研究对于解决PCI后的CMD知识差距至关重要.
- 识别和解决CMD复杂的病因是改善PCI结果的关键.
- 未来的研究应该专注于CMD的新型诊断和治疗方法.
相关概念视频
Acute Coronary Syndrome IV: Interprofessional Care
200
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
200
Coronary Artery Disease V: Interprofessional Care
205
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
205
Peripheral Artery Disease III: Interprofessional Care
226
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
226
Coronary Artery Disease II: Pathophysiology
342
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
342
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
325
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
325
Angina IV: Management
219
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
219


